109 search results for: symposium
How often do you suggest to assess sense of smell?
Prof. Mullol highlights the utility of visual analog scale for quick assessment of sense of smell in patients with CRSwNP.
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
World Congress on Itch (WCI) 2023 | Miami
Exploration of the shared mechanisms of itch across AD, PN, and CSU as well as the distinct ways itch manifests in each disease.
Bullous Pemphigoid (BP): Exploring New Frontiers
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia
Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
ADVENT at EADV 2024
Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
What do we mean by disease control in AD?
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis
This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.
